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OBJECTIVE—The G-protein–coupled receptor GPR40 medi-
ates fatty acid potentiation of glucose-stimulated insulin secre-
tion, but its contribution to insulin secretion in vivo and
mechanisms of action remain uncertain. This study was aimed to
ascertain whether GPR40 controls insulin secretion in vivo and
modulates intracellular fuel metabolism in islets.
RESEARCH DESIGN AND METHODS—Insulin secretion and
sensitivity were assessed in GPR40 knockout mice and their
wild-type littermates by hyperglycemic clamps and hyperinsu-
linemic euglycemic clamps, respectively. Transcriptomic analy-
sis, metabolic studies, and lipid proﬁling were used to ascertain
whether GPR40 modulates intracellular fuel metabolism in islets.
RESULTS—Both glucose- and arginine-stimulated insulin secre-
tion in vivo were decreased by 60% in GPR40 knockout fasted
and fed mice, without changes in insulin sensitivity. Neither gene
expression proﬁles nor intracellular metabolism of glucose and
palmitate in isolated islets were affected by GPR40 deletion.
Lipid proﬁling of isolated islets revealed that the increase in
triglyceride and decrease in lyso-phosphatidylethanolamine spe-
cies in response to palmitate in vitro was similar in wild-type and
knockout islets. In contrast, the increase in intracellular inositol
phosphate levels observed in wild-type islets in response to fatty
acids in vitro was absent in knockout islets.
CONCLUSIONS—These results indicate that deletion of GPR40
impairs insulin secretion in vivo not only in response to fatty
acids but also to glucose and arginine, without altering intracel-
lular fuel metabolism in islets, via a mechanism that may involve
the generation of inositol phosphates downstream of GPR40
activation. Diabetes 58:2607–2615, 2009
S
ince its deorphanization in 2003 (1,2), the G-
protein–coupled fatty acid receptor GPR40,
highly expressed in pancreatic -cells, has drawn
considerable attention as a potential therapeutic
target for type 2 diabetes. Fatty acids amplify insulin
secretion from the -cell only in the presence of glucose.
This incretin-like effect could be exploited to develop
novel therapeutic agents to enhance glucose-stimulated
insulin secretion (GSIS) in type 2 diabetes (3). Previous
studies in our laboratory have shown that GPR40 contrib-
utes to 50% of fatty acid potentiation of insulin secretion
in vitro and in vivo (4). In addition, recent reports (4–7)
provide evidence that activation of GPR40 may represent a
beneﬁcial approach to enhance insulin secretion in type 2
diabetes. However, several key questions remain to be
answered regarding the role of GPR40 in insulin secretion.
Whereas it is clear that GPR40 mediates, at least in part,
fatty acid potentiation of insulin secretion, its contribution
to the secretory action of other fuel and nonfuel stimuli in
vivo is not known. This issue is important because 1) fatty
acids are always present in the circulation and therefore
may inﬂuence the response to various secretagogues and
thereby the overall regulation of insulin secretion in vivo,
2) lipid signaling is an integral part of the regulation of
insulin secretion in response to glucose and other secre-
tagogues (8), and 3) our previous results suggest impaired
insulin secretion in response to glucose in high-fat–fed
GPR40 knockout mice (5), and a recent study reported
increased GSIS in vitro in islets from GPR40 transgenic
mice (9). In addition, the mechanisms of action of
GPR40 are incompletely understood. It was shown to
couple to the G-protein subunit Gq/11 (2) and in turn
activate phospholipase C (PLC)-mediated hydrolysis of
phosphatidylinositol 4,5-biphosphate into diacylglycerol
(DAG) and inositol phosphates (InsPs), which activate
protein kinase C and mobilize Ca
2 from the endoplas-
mic reticulum, respectively (rev. in 10). A rise in cyto-
plasmic Ca
2 has been linked to the activation of
dehydrogenases involved in pyruvate mitochondrial
metabolism, such as pyruvate-, -ketoglutarate–, and
isocitrate-dehydrogenase (11), raising the possibility
that GPR40 activation modulates intracellular fuel me-
tabolism. The present study was therefore aimed to
determine whether deletion of GPR40 1) alters insulin
secretion in response to fuel and nonfuel secretagogues
and insulin sensitivity in vivo and 2) affects intracellular
fuel metabolism in islets.
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Reagents. Twenty percent dextrose solution was from Baxter (Mississauga,
ON, Canada), RPMI 1640, and FBS were from Invitrogen (Burlington, ON,
Canada). Fatty acid–free BSA was from Equitech-Bio (Kerrville, TX). Radio-
active tracers were from GE Healthcare (Baie d’Urfe ´, QC, Canada), and all
other reagents were from Sigma (St. Louis, MO), unless otherwise noted. The
fatty acid enzymatic kit was from Wako Chemicals (Neuss, Germany).
Animals. GPR40 knockout mice were generated as described (4) and
backcrossed to the C57BL/6 strain for more than seven generations at Amgen
(San Francisco, CA). All procedures were approved by the institutional
committee for the protection of animals at the Centre Hospitalier de
l’Universite ´ de Montre ´al.
-Cell mass. Freshly excised whole pancreata (from fed 12- to 14-week-old
mice) were trimmed of fat, weighed, ﬁxed in 4% buffered paraformadehyde,
and embedded in parafﬁn with 5-m sections mounted on glass slides for
immunohistochemical and -cell mass analyses, as previously described (4).
Whole-body fat content. The percentage of whole-body fat content in fed
GPR40 wild-type and knockout (12–14 weeks old) mice was assessed using an
EchoMRI-700 (Houston, TX).
Assessment of insulin secretion and sensitivity by hyperglycemic and
euglycemic-hyperinsulinemic clamp. One-step hyperglycemic clamps were
performed on conscious animals. A 20% dextrose solution was infused
through the jugular vein to clamp plasma glucose at 350 mg/dl for 60 min and
was adjusted based on glucose measurements (Roche Accu-Check; Roche,
Indianapolis, IN). At 60 min, an arginine bolus injection was performed (1
mmol/kg; Sandoz Canada) to assess the maximal insulin response. Plasma
samples were collected from the tail at several time points during the clamp
for insulin measurements using a mouse insulin enzyme-linked immunosor-
bent assay (ELISA) kit (Alpco Diagnostics, Salem, NH). Plasma samples for
C-peptide measurements were collected at 45 min and analyzed using a mouse
C-peptide ELISA kit (Alpco Diagnostics). Two-hour hyperinsulinemic-eugly-
cemic clamps were performed in 5-h food-restricted GPR40 wild-type and
knockout mice. Following a 1-min bolus insulin infusion (85 mU/kg; Humulin
R), insulin was infused at 5 mU  kg
1  min
1. Twenty percent dextrose was
infused starting 5 min after the insulin infusion to clamp glycemia at 140
mg/dl. The insulin sensitivity index (M/I) was calculated as the glucose
infusion rate (M) divided by the average insulinemia during the last 30 min of
the clamp (I).
Transcriptomic study. Islets were isolated from GPR40 wild-type and
knockout fed mice (13–15 weeks old, n  5 for each genotype) as previously
described (4). Total RNA was extracted from pancreatic islets using an
RNeasy Micro kit (Qiagen) in accordance with the manufacturer’s protocol as
previously described (5). Total RNA was stored at 80°C for microarray
hybridization (see supplemental RESEARCH DESIGN AND METHODS in the online
appendix [available at http://diabetes.diabetesjournals.org/cgi/content/full/
db09-0362/DC1]).
Metabolic studies in islets. Islets were isolated from 24-h–fasted or ad
libitum–fed mice (12–14 weeks old) as previously described (4). Freshly
isolated islets were recovered at 37°C for 30 min in Krebs-Ringer bicarbonate
HEPES buffer (KRBH)/0.25% BSA supplemented by 2.8 mmol/l glucose.
Palmitate and control solutions were prepared as previously described (12).
For measurements of glucose oxidation and utilization, batches of 20 islets
were incubated in KRBH/0.25% BSA containing 1Ci D-[U-
14C]-glucose (250
mCi/mmol) and 0.5 Ci D-[5-
3H]-glucose (16 Ci/mmol) at 2.8 or 16.7 mmol/l
glucose for 2 h. Glucose oxidation was measured by the generation of
KOH-trapped
14CO2, and glucose utilization was determined by measuring the
amount of
3H2O generated as described previously (13). To measure fatty acid
oxidation and incorporation in total lipids, batches of 50 islets were incubated
in KRBH/0.25% BSA, 0.1 mmol/l palmitate, 1 mmol/l carnitine, 2Ci/ml
[9,10(n)-
3H] palmitate (51 Ci/mmol), and 2.8 or 16.7 mmol/l glucose for 2 h.
Supernatants were transferred to Eppendorf tubes for separation of
3H2O
from labeled fatty acids as previously described (14). The remaining islets
were washed and sonicated in water. Total lipids were extracted using the
Folch method. Radioactivity incorporation was counted on the lipid soluble
fractions.
Fatty acid esteriﬁcation. Islets isolated from fed mice were cultured
overnight in RPMI supplemented with 10% FCS (complete RPMI) at 11 mmol/l
glucose. Fatty acid esteriﬁcation was determined in batches of 70 islets
incubated for4hi nt h esame conditions as described above. After the
incubation, total lipids were extracted and subjected to separation by thin-
layer chromatography as described (15).
Lipid proﬁling. Islets isolated from fed mice were cultured overnight in
complete RPMI medium at 11 mmol/l glucose. Batches of 250 islets each were
incubated for1ha t2 . 8mmol/l glucose in RPMI and then exposed to 16.7
mmol/l glucose with or without 0.5 mmol/l palmitate for 1 h. Total lipids were
extracted using the Folch method, dried, and stored at 80°C for liquid
chromatography–mass spectrometry analysis (see supplemental RESEARCH
DESIGN AND METHODS).
Arachidonic acid release. Islets isolated from fed mice were cultured
overnight in complete RPMI medium at 5.6 mmol/l glucose and 4 Ci/ml [5, 6,
8, 9, 11, 12, 14, 15(n)-
3H] arachidonic acid (AA) (250 Ci/mmol
3H-AA). After
prelabeling,
3H-AA release was measured in islets incubated at 16.7 mmol/l
glucose, with or without 0.5 mmol/l palmitate or 100 mol/l carbachol in
KRBH/0.6% BSA for 30 min as described (16). After incubation, islets were
lysed to measure incorporation of the total radioactivity.
Intracellular inositol phosphate accumulation. Islets isolated from fed
mice were cultured overnight in complete RPMI medium at 11.1 mmol/l
glucose. Batches of 40 islets were prelabeled with 7.5 Ci of [
3H]myo-inositol
(95 Ci/mmol) in KRBH/0.01% BSA for 3 h. After prelabeling, InsPs accumula-
tion was measured in islets incubated at 16.7 mmol/l glucose, with or without
30 mol/l oleate or 1 mmol/l carbachol in KRBH/0.01% BSA/10 mmol/l LiCl for
20 min. After incubation, islets were lysed in 20 mmol/l formic acid (150 l),
and
3H-InsPs content was measured using the Yttrium silicate scintillation
proximity assay (YSi SPA) beads (GE Healthcare) (17). Brieﬂy, YSi SPA beads
were diluted eightfold with water, 100 l of diluted beads were added to each
well of a Wallac Isoplate-96 white plate (Perkin Elmer, Woodbridge, ON,
Canada) followed by 50 l of islets extracts, and radioactivity was measured
using a MicroBeta TriLux scintillation counter (Perkin Elmer) after a 2-h
incubation.
Expression of data and statistics. Data are expressed as means  SE.
Intergroup comparisons were performed by ANOVA, with post hoc adjust-
ments for two-by-two comparisons or Student’s t test, as appropriate. P 	 0.05
was considered signiﬁcant.
RESULTS
Insulin secretion is impaired in GPR40 knockout
mice during hyperglycemic clamps. Basal metabolic
parameters were ﬁrst compared between 24-h–fasted and
ad libitum–fed male GPR40 knockout mice (back-crossed
onto the C57Bl/6J for seven generations) and their wild-
type littermates (Table 1). As expected, plasma fatty acid
levels were signiﬁcantly increased, while both glucose and
insulin levels were signiﬁcantly decreased, in fasted versus
fed mice. Blood glucose, fatty acids, insulin, and C-peptide
levels were similar in GPR40 knockout and wild-type mice
in both the fed and fasted state, consistent with our
previous report (4). Insulin secretion in response to glu-
cose and arginine was assessed in vivo using 1-h hypergly-
cemic clamps (Fig. 1A and D). As expected, the glucose
infusion rate was markedly lower in fasted than in fed
animals, although it was not affected by the genotype
when taking into account the prevailing insulin levels
(Table 2). Insulin secretion during the clamp was mark-
edly decreased in both fasted and fed GPR40 knockout
TABLE 1
Metabolic parameters of GPR40 wild-type and knockout mice
and -cell mass
Wild type Knockout
Basal 24-h–fasted mice
Body weight (g) 24.1  0.2 25.1  0.5
Basal glycemia (mg/dl) 120  5 119  9
Free fatty acids (mmol/l) 0.50  0.03 0.55  0.03
Basal insulinemia (ng/ml) 0.06  0.01 0.08  0.01
C-peptide (ng/ml) 0.51  0.04 0.49  0.01
Basal fed mice
Body weight (g) 28.2  0.9* 27.8  0.5*
Basal glycemia (mg/dl) 151  3† 154  5†
Free fatty acids (mmol/l) 0.09  0.01† 0.11  0.02†
Basal insulinemia (ng/ml) 0.48  0.01† 0.51  0.03†
C-peptide (ng/ml) 0.64  0.03* 0.71  0.02*
-Cell mass (mg) 1.55  0.09 2  0.22
Fat (% of body weight) 12  11 0  1
Data are means  SE. n  7–9 mice/group. *P 	 0.05; †P 	 0.01 vs.
fasted.
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over the ﬁrst 60 min of the clamp were reduced in fasted
and fed GPR40 knockout mice by approximately twofold
and approximately threefold, respectively (Table 2). Ac-
cordingly, C-peptide concentrations 45 min into the clamp
were signiﬁcantly lower in GPR40 knockout fed animals
versus wild type (1.45  0.13 ng/ml [n  7] vs. 2.04  0.17
ng/ml [n  9]; P 	 0.05). Arginine potentiation of GSIS was
also decreased by approximately threefold in fasted and
fed GPR40 knockout mice (Table 2) (Fig. 1C and F).
Similar observations were made in female GPR40 knock-
out mice (not shown). -Cell mass (Table 1) and islet size
distribution (not shown) were not different between
GPR40 wild-type and knockout mice. Insulin sensitivity
was then examined in hyperinsulinemic-euglycemic
clamps. Both the glucose infusion rate (Fig. 2B) required
to maintain glycemia at 140 mg/dl (Fig. 2A) during the
clamp and the insulin sensitivity index (Fig. 2C) were
similar in GPR40 wild-type and knockout mice. Thus,
GPR40 deletion does not affect whole-body insulin sensi-
tivity, consistent with previous reports using insulin toler-
ance tests (4,18). Altogether, our data demonstrate that
GPR40 deletion impairs insulin secretion in vivo in re-
sponse to glucose and arginine without altering insulin
sensitivity.
Intracellular metabolism of glucose and fatty acids in
islets is not affected by GPR40 deletion. Transcrip-
tomic analysis, metabolic studies, and lipid proﬁling were
used to address whether GPR40 modulates intracellular
fuel metabolism in islets. We ﬁrst assessed the impact of
GPR40 deletion on the islet transcriptome using expres-
sion microarrays. Approximately 1,770 genes were sig-
niﬁcantly modulated (1,109 downregulated and 661
upregulated) in knockout versus wild type (P 	 0.05).
However, expression of none of these genes was changed
more than twofold (supplementary Fig. S1). Thus, GPR40
deletion does not have a major impact on the islet tran-
scriptome. To explore the functional impact of GPR40
deletion on fuel partitioning, glucose and palmitate metab-
olism were assessed in islets isolated from 24-h–fasted and
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FIG. 1. Hyperglycemic clamps in 24-h–fasted and ad libitum–fed GPR40 wild-type and knockout mice. Glucose (A and D) and insulin (B and E)
levels during the course of the hyperglycemic clamp in fasted and fed GPR40 wild-type and knockout mice. Insulin levels (C and F) in response
to an arginine bolus (1 mmol/kg). Values are expressed as means  SE of seven to nine mice per group. , Wild type; F, knockout.
TABLE 2
Insulin secretion in GPR40 wild-type and knockout during hyper-
glycemic clamps
Wild type Knockout
Hyperglycemic clamp in 24-h–fasted
mice
AUCInsulin T0–60 min 51.6  9.6 24.9  6.9*
AIRMax (ng/ml) T61 min 5.7  1.3 2.1  0.6*
GIR (mg  kg
1  min
1) 16  5 10.5  1
Hyperglycemic clamp in fed mice
AUCInsulin T0–60 min 65.4  17.2 19.3  6.9*
AIRMax (ng/ml) T61 min 11.8  1.9 3.9  0.5†
GIR (mg  kg
1  min
1) 71  9§ 39  4†§
Data are means  SE. n  7–9 mice/group. *P 	 0.05; †P 	 0.01 vs.
wild type. §P 	 0.01 vs. fasted. AIR Max, maximal arginine-induced
insulin response; AUCInsulin, area under the curve of insulin; GIR,
glucose infusion rate.
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cantly increased glucose utilization and oxidation, de-
creased palmitate oxidation by 3-fold, and increased
palmitate esteriﬁcation by 1.5-fold in both fasted and fed
wild-type islets (Fig. 3A–D). No differences were observed
between wild-type and knockout islets for any of these
measurements (Fig. 3A–D). Consistent with previous stud-
ies (19,20), fasting decreased glucose oxidation and palmi-
tate esteriﬁcation and increased palmitate oxidation (Fig.
3A–D).
Palmitate esteriﬁcation into phospholipids (PLs), triac-
ylglycerol (TAG), DAG, and fatty acids was assessed in
islets isolated from fed wild-type and knockout mice.
Raising glucose from 2.8 to 16.7 mmol/l increased palmi-
tate esteriﬁcation into DAG and TAG and increased fatty
acid content similarly in wild-type and knockout islets
(Fig. 4A and B). The effect of elevated glucose on palmitate
esteriﬁcation in PLs, DAG, TAG, and on intracellular fatty
acid levels was not different between wild-type and knock-
out islets. These data indicate that GPR40 deletion does
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does it contribute to changes in intracellular fuel metabo-
lism in response to fasting.
The islet lipid proﬁle is modulated acutely by palmi-
tate independently of GPR40. Data presented in Figs. 3
and 4 indicate that GPR40 deletion does not alter ﬂuxes
through major glucose and palmitate metabolic pathways.
This does not rule out the possibility that GPR40 might
modulate the abundance of individual lipid species in
islets in response to palmitate. This possibility was tested
using liquid chromatography–mass spectrometry–based
lipid proﬁling. Islets isolated from wild-type and knockout
mice were incubated for 1 h at 16.7 mmol/l glucose  0.5
mmol/l palmitate. Lipid-soluble fractions were separated
by liquid chromatography followed by tandem mass
spectrometry analysis as described in the supplemental
RESEARCH DESIGN AND METHODS. The data are presented as
relative abundance (i.e., comparative mass measurements
across samples) after log2 transformation (Fig. 5). Palmi-
tate treatment signiﬁcantly modulated the relative abun-
dance of 59 lipid species in wild-type islets and 62 in
knockout islets (P 	 0.05) (see supplementray Fig. S2),
among which 13 were identiﬁed based on their match with
the accurate mass and time tag database (see supplemen-
tal RESEARCH DESIGN AND METHODS). Several TAG species were
markedly increased by palmitate treatment both in wild-
type and knockout islets (Fig. 5A). For example, the
abundance of TAG 48:1 was increased ﬁvefold (2.3 log2
units) in wild-type islets in response to palmitate. Al-
though the effect of palmitate was more pronounced for
some TAG in wild-type versus knockout islets, when
calculated as fold increase over control, no signiﬁcant
differences were observed between wild-type and knock-
out islets. These results indicate that acute palmitate
treatment induces a robust increase in several TAG
species in islets independently of GPR40. Palmitate
treatment decreased the abundance of all identiﬁed
lyso-phosphatidylethanolamine (LPE) species (Fig. 5B)
but did not have a major effect on lyso-phosphatidylcho-
lines (LPC) (Fig. 5B), phosphatidylethanolamines (PEs)
(supplementary Fig. S3A), phosphatidylcholines (PCs)
(supplementary Fig. S3A), or sphingomyelins (supple-
mentary Fig. S3B). Although the effect of palmitate was
more pronounced for some LPE in knockout versus
wild-type islets (Fig. 5B), when calculated as fold de-
crease over control, no difference was observed be-
tween the two genotypes. These data indicate that
palmitate modulates LPE abundance independently of
GPR40. Several lines of evidence suggest that hydrolysis
of membrane PLs by phospholipase A2 (PLA2) into
lyso-PLs and AA participates in the control of insulin
secretion (21–24). We therefore tested whether palmi-
tate lowering of LPE content results from PLA2-medi-
ated PL hydrolysis. PLA2 activity was indirectly
assessed in islets by measuring the release of AA as
previously described (16). The muscarinic agonist car-
bachol stimulated AA release to a similar extent in
wild-type and knockout islets, while palmitate had no
effect (Fig. 6A). We conclude that 1) palmitate potenti-
ation of GSIS is independent of AA release and 2)
activation of the PLA2 pathway is not affected by GPR40
deletion.
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FIG. 4. Palmitate esteriﬁcation in GPR40 wild-type and knockout islets. Palmitate esteriﬁcation into triacylglycerol (A), diacylglycerol (B),
nonesteriﬁed fatty acid (C), and phospholipids (D) in islets incubated at 2.8 () or 16.7 (f) mmol/l glucose for 4 h. Data are expressed as
means  SE of ﬁve independent experiments. *P < 0.05 or **P < 0.01 vs. 2.8 mmol/l glucose.
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tion of inositol phosphates in response to oleate.
Previous studies suggest that GPR40 couples to the G-
protein subunit Gq/11 (2) and in turn activates PLC-
mediated hydrolysis of phosphatidylinositol into DAG and
InsPs (25). Furthermore, pharmacological inhibition of
Gq (4,26) or PLC (26,27) in -cells prevents fatty acid
potentiation of GSIS. However, whether GPR40 mediates
fatty acid–induced InsPs generation in islets is unknown.
To address this question, we compared InsPs generation
from tritiated phosphoinositides in response to oleate in
islets from wild-type and GPR40 knockout mice (Fig. 6B).
Remarkably, the increase in InsPs accumulation observed
in wild-type islets in response to oleate was absent in
knockout islets. In contrast, InsPs accumulation in re-
sponse to the muscarinic agonist carbachol was similar in
both groups (1.9  0.3–fold increase in knockout islets vs.
2.0  0.7–fold increase in wild-type islets; n  3; NS).
These data indicate that fatty acid–induced InsPs accumu-
lation is dependent upon GPR40 in mouse islets.
DISCUSSION
The objectives of this study were to examine whether
deletion of GPR40 impairs insulin secretion in vivo and
modulates intracellular fuel metabolism in islets. We
found that, in GPR40 knockout mice, insulin secretion in
response to both glucose and arginine is impaired in fed
and fasted animals during hyperglycemic clamps, without
changes in insulin sensitivity, as measured by hyperinsu-
linemic-euglycemic clamps. This was associated with a
complete absence of fatty acid–induced intracellular InsPs
accumulation in islets, without detectable changes in
intracellular glucose or fatty acid metabolism. We con-
clude that GPR40 signaling is implicated in the regulation
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fuel metabolism.
Our results demonstrate that deletion of GPR40 impairs
insulin secretion in response to glucose and arginine in
vivo under fasted and fed conditions. Since neither -cell
mass nor insulin content (not shown) were affected by
GPR40 deletion, we infer that the decrease in insulin levels
in GPR40 knockout mice results from a bona ﬁde secre-
tory defect. This conclusion is further supported by the
observed decrease in circulating C-peptide levels during
the hyperglycemic clamp. Since fatty acids are always
present in the circulation in vivo, we suggest that GPR40
mediates their potentiating action on glucose- and argin-
ine-stimulated insulin secretion. Consistent with this view,
GSIS ex vivo was similar in wild-type and knockout islets
isolated from fasted mice (not shown). In addition, we
have previously shown that the islet response to glucose
alone in the absence of exogenous fatty acids is not
affected by GPR40 deletion, whereas the response to fatty
acids is markedly decreased (4). The observed impairment
of insulin secretion in this study using hyperglycemic
clamps is in apparent contradiction with our previous
ﬁndings that insulin secretion was similar in wild-type and
knockout mice when assessed by intravenous glucose
tolerance tests (IVGTTs) (4,5). One possible explanation
for this discrepancy is that the single bolus of glucose in
the IVGTT mostly stimulates ﬁrst-phase insulin release,
which relies less on the ampliﬁcation pathway of insulin
secretion than the full ﬁrst- and second-phase secretory
proﬁle induced under clamp conditions. Also, sustained
glucose stimulation during the clamp evokes a greater
integrated insulin response than the IVGTT bolus and is
therefore more likely to detect secretory defects.
Using transcriptomic, metabolic, and lipid-proﬁling ap-
proaches, we tested the hypothesis that impaired insulin
secretion in GPR40 knockout mice involves modulation of
intracellular fuel metabolism in islets. First, microarray
analyses indicated that GPR40 deletion does not alter the
expression of islet genes by more than twofold, suggesting
that the defect in insulin secretion is not related to major
changes in islet phenotype. Second, neither glucose nor
palmitate metabolism (as assessed by tracer studies) was
modiﬁed in fasted or fed GPR40 knockout islets, nor were
there any signiﬁcant differences in lipid proﬁles using
liquid chromatography–mass spectrometry between wild-
type and knockout islets in response to palmitate. Third,
AA generation was unaltered by GPR40 deletion. In con-
trast, InsPs accumulation in response to oleate was com-
pletely absent in GPR40 knockout islets. Together with
previous studies from our (4) and other (26,27) groups
using pharmacological inhibitors of the Gq/11 signaling
pathway, these data therefore reinforce the notion that the
mode of regulation of insulin secretion by GPR40 involves
receptor-mediated signaling rather than fuel-derived met-
abolic signals. This conclusion has important implications
for the understanding of the mechanisms of action of fatty
acids on the -cell. On the one hand, molecular and
pharmacological approaches have shown that fatty acid
activation to fatty acyl-CoA and intracellular metabolism
are required for their potentiating effects on GSIS (8). On
the other hand, several studies have reported that block-
ade of GPR40 signaling prevents, at least in part, fatty acid
potentiation of GSIS (2,4,26,28,29). This suggested that
perhaps these two mechanisms of action (intracellular
metabolism and GPR40 activation) were interrelated. The
results of the present study show that, to the contrary,
fatty acid signaling through GPR40 is independent from
their intracellular metabolism. They further suggest that in
this context, the GPR40-dependent rise in intracellular
Ca
2 levels does not signiﬁcantly affect the activity of the
tricarboxylic acid cycle, as measured by fuel oxidation.
Based on our previous observation that GPR40 deletion
results in a 50% decrease in insulin secretion in response
to fatty acids in vivo (4), we propose that GPR40 signaling
contributes approximately half of the potentiating effects
of fatty acids on GSIS.
Liquid chromatography–mass spectrometry–based lipid
proﬁling showed that acute palmitate treatment markedly
increased several TAG species and decreased LPE species
independently from GPR40. To our knowledge, this is the
ﬁrst direct demonstration that acute exposure of islets to
palmitate rapidly results in a dramatic (ﬁvefold for some
species) increase in different TAG species. It suggests that
intermediates generated along the TAG synthesis pathway
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FIG. 6. Arachidonic acid release and InsPs accumulation in GPR40 wild-type and knockout islets. A: AA release in islets incubated during 30 min
at 16.7 mmol/l glucose with or without 0.5 mmol/l palmitate and 100 mol/l carbachol. AA efﬂux is expressed as the percentage release of total
incorporated radioactivity. Data are expressed as means  SE of three to four independent experiments. **P < 0.01 vs. control. B: InsPs
accumulation in islets incubated during 20 min at 16.7 mmol/l glucose with or without 30 mol/l oleate. InsPs accumulation is expressed as fold
changes over control conditions (16.7 mmol/l glucose). Data are expressed as means  SE of three independent experiments. *P < 0.05 vs.
control. , Wild type; f, knockout.
T. ALQUIER AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 58, NOVEMBER 2009 2613might be implicated in GPR40-independent ampliﬁcation
of GSIS by fatty acids. Whether this is also associated with
increased rates of lipolysis and an increase in TAG–fatty
acid cycling (30) remains to be determined. A potential
mechanism for the palmitate-induced decrease in LPE
involves LPE reesteriﬁcation by lyso-PL-acyltransferase
(Lands cycle) (31). Such a mechanism is consistent with
the observed increase in PE 36:4 and PE 18:0p/20:4 (sup-
plementary Fig. S3A). Whether this mechanism plays a
role in fatty acid potentiation of GSIS remains to be
investigated. LPC was recently shown to potently enhance
GSIS via activation of the GPR119 receptor (32,33). Both
LPE and LPC are generated by plasma membrane–associ-
ated PLA2 activities known to stimulate insulin secretion
(34), and a recent report suggested that fatty acids modu-
late the PLA2 pathway and the generation of AA via GPR40
in primary hepatocytes (35). However, although we have
not directly measured the activity of the enzyme, our
ﬁnding that AA release is not increased by palmitate does
not support the hypothesis that the effects of palmitate on
GSIS are mediated by PLA2.
GPR40 expression has been detected in the ileum (1,2),
monocytes (1), pancreatic -cells (36), some areas of the
brain (1,37), entero-endocrine cells (38), and osteoclasts
(39), albeit at much lower levels than in -cells. Conse-
quently, we cannot exclude that deletion of GPR40 in
these tissues in our global knockout model could have
contributed to the insulin secretory defect. However, there
was not apparent change in body weight, food intake, or
insulin sensitivity in these mice, and the main phenotype
appears restricted to the -cell. Therefore, we believe that
the contribution of non–-cells to the observed phenotype,
if any, is minimal, although a tissue-speciﬁc knockout
model would be required to formally exclude this
possibility.
In conclusion, this study identiﬁes GPR40 as necessary
for insulin secretion in vivo. The impaired insulin secre-
tion observed in GPR40 knockout mice is independent of
nutrient metabolism in islets and more likely involves the
canonical GPR40 signaling pathway.
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